Thymosin Alpha-1 + KPV:
Immune Research Protocol Guide

Thymosin Alpha-1: Thymic and Adaptive Immunity

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymosin fraction 5 by Allan Goldstein's group at George Washington University in the 1970s. It drives maturation of T lymphocytes within the thymus, enhances NK cell activity, augments IL-2 and IFN-gamma production, and upregulates MHC class I expression on tumour cells.

Its clinical credentials are the most extensive of any peptide in the immune modulation category. Thymalfasin (synthetic Tα1) is approved in 37 countries as an adjunct treatment for hepatitis B and C, and has been used as an immunotherapy adjuvant in multiple clinical settings. This regulatory history provides researchers with a substantial human safety database — unusual for a research peptide.

KPV: NF-kB Inhibition and Mucosal Immunity

KPV (Lys-Pro-Val) is a tripeptide C-terminal fragment of alpha-melanocyte stimulating hormone (α-MSH). It directly inhibits NF-kB translocation to the nucleus, reducing the transcription of pro-inflammatory cytokines including TNF-alpha, IL-1β, and IL-6. Unlike systemic immunosuppressants, KPV's NF-kB inhibition appears tissue-specific, with particularly strong effects at mucosal surfaces.

Multiple IBD models (DSS-induced colitis, TNBS colitis) have shown KPV administered orally or intraperitoneally reduces colonic inflammation, maintains mucosal barrier integrity, and decreases myeloperoxidase activity. Oral bioavailability is a notable feature — KPV's tripeptide structure survives partial GI transit, making oral capsule administration relevant for gut-targeted immune research.

Research Protocol

Thymosin Alpha-1 Dosing

• Standard: 1.5 mg subcutaneous injection, twice weekly
• Intensive (clinical-derived): 1.6 mg twice weekly for 6 months (hepatitis B protocol dosing)
• Duration: 10–16 weeks for immune research; longer cycles studied in clinical settings
• Reconstitute 5mg in 3.2mL bac water → 1.5625 mg/mL → 1.5mg dose ≈ 0.96mL

KPV Dosing

• Systemic (subcutaneous): 250–500 mcg once or twice daily
• Gut-targeted (oral capsule): 500 mcg–1 mg once daily, fasted
• Oral capsule format preferred for gut mucosal research; subcutaneous for systemic effects

Combined Protocol Example

• Thymosin Alpha-1: 1.5mg SC twice weekly (Mon + Thu)
• KPV: 500 mcg oral capsule daily (continuous)
• Week 1–12: Combined protocol
• Optional: Add BPC-157 250 mcg twice daily oral for enhanced gut mucosal repair coverage

BPC-157 as a Third Compound

The full Immune Modulation Stack adds BPC-157 to address gut wall integrity separately from the inflammatory response. BPC-157 promotes VEGF-driven angiogenesis in the gut mucosa and accelerates healing of intestinal lesions in multiple rodent models. The combination of BPC-157 (structural repair) + KPV (inflammatory suppression) + Thymosin Alpha-1 (immune cell maturation) covers three distinct but synergistic aspects of gut-immune research.